Health Canada recalls Jamp acetaminophen due to safety concerns

Health Canada has issued a recall for Jamp's acetaminophen tablets due to potential inaccuracies in dosage. The recalled products include 325 milligram and 500 milligram tablets, which may contain either more or less than the recommended dosage of the active ingredient. This discrepancy poses serious health risks, particularly for patients relying on accurate dosing for effective treatment. The affected lot numbers for the 325 milligram tablets are EG22AMP013, EG22AMP014, and EG22AMP015, while the 500 milligram tablets include EG22AMQ034, EG22AMQ035, EG22AMQ036, and EG22AMQ042. In addition to acetaminophen, the recall also affects clopidogrel, a medication critical for preventing blood clots. Incorrect dosages of clopidogrel can lead to severe health complications, including an increased risk of stroke and heart attack. Patients may experience adverse effects from both underdosing and overdosing, with symptoms ranging from bleeding issues to gastrointestinal distress. Health Canada has advised patients to consult healthcare providers before discontinuing any medication. Consumers who have purchased the affected products are urged to check the recall list and return any recalled items to their pharmacy. It is crucial for patients to avoid stopping their medication abruptly without a suitable replacement, as this could exacerbate their health conditions. The recall highlights the importance of accurate medication dosing and the potential dangers associated with pharmaceutical errors. Health Canada continues to monitor the situation and has emphasized the need for vigilance among consumers regarding their medications. The agency's proactive measures aim to ensure public safety and maintain trust in pharmaceutical products.